Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

HCV: early-phase trial registry

3 of 9 indexed HCV trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

HCV: 9 US clinical trials tracked, 3 recruiting.

HCV is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI), running 1 of these trials.

Enrollment posture brief

Registry condition hcv

OPEN 3 | RECR 33% | LATE 0 | EARLY 2 | RANK #1916 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%HCV (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near HCV

HCV lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HCV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HCV is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of HCV trials is spread across many organizations.

    North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical HCV enrolment sits around 141 participants.

    Median target enrolment is 141 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.

  4. HCV research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Open and recent trials

9 total, page 1 of 1

RECRUITING NA 285 participants

A Setting Focus Overdose Prevention Intervention

Johns Hopkins Bloomberg School of Public Health

NCT05320835

RECRUITING NA 141 participants

Appalachian Partnership to Reduce Disparities (Aim 2)

Wake Forest University Health Sciences

NCT04378439

RECRUITING NA 120 participants

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Johns Hopkins University

NCT05653232

ACTIVE NOT RECRUITING NA 446 participants

Integrated HIV Prevention and HCV Care for PWID

Columbia University

NCT03981445

ACTIVE NOT RECRUITING 198 participants

Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

University of Maryland, Baltimore

NCT03221309

ACTIVE NOT RECRUITING NA 69 participants

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)

NCT06316739

COMPLETED Phase 2 275 participants

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Atea Pharmaceuticals

NCT05904470

COMPLETED Phase 1 47 participants

TD-6450 MAD Study in HCV Infected Subjects

Theravance Biopharma

NCT02116543

COMPLETED 8 participants

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Hoffmann-La Roche

NCT02452814

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on HCV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

TD-6450 Drug
1 trials
Ruzasvir Drug
1 trials
Bemnifosbuvir Drug
1 trials
Adherence Counseling Behavioral
1 trials
ARTAS Adapted Patient Navigation Behavioral
1 trials
Ganchero intervention Behavioral
1 trials
Evaluate model of care for HCV-infected adults with on-going opioid misuse Other
1 trials
Peer Navigation Behavioral
1 trials

US sites by state

Facility locations filed on HCV trials. A trial with sites in several states counts in each.

Texas 3 trials
New York 3 trials
Maryland 3 trials
Wisconsin 1 trials
Virginia 1 trials
Utah 1 trials
Pennsylvania 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HCV page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HCV condition card totals 9 registered trials; most-linked intervention TD-6450; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.